3850 – Anti-GP2 IgG

Intended Use

The Anti-GP2 IgG is a quantitative immunoassay for the determination of IgG antibodies against glycoprotein 2 (GP2) in human serum. The Anti-GP2 IgG is intended as an aid in the diagnosis of Crohn’s disease in conjunction with other clinical and laboratory findings. The immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

Non-specific inflammatory bowel disease including Crohn’s disease (CD) (Enteritis regionalis) and ulcerative colitis (UC) are characterised by chronic-remitting inflammatory processes of the intestine. Immunologic, genetic, infectious and environmental factors have been identified as the risk factors of developing one of these diseases. Autoantibodies of exocrine pancreas (PAB) have been identified as specific serological marker for CD. Membrane-bound pancreatic Glycoprotein 2 (GP2) is the major target of PAB’s. PAB’s against GP2, in combination with the detection of autoantibodies to Saccharomyces cerevisiae (ASCA), which is highly prevalent (70 %) in patients with CD and atypical antineutrophil cytoplasmatic antigens (aANCA), mainly found in patients with UC, could be used as a highly specific serological marker for differential diagnosis of CD to UC.